Seeking Alpha: Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress Results from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits with SRD-002 gene therapy The MUSIC-HFpEF trial is investigating SRD-002, a one-time gene ... Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress Heart failure with preserved ejection fraction (HFpEF, hef-PEF) is a form of heart failure in which the ejection fraction – the percentage of the volume of blood ejected from the left ventricle with each heartbeat divided by the volume of blood when the left ventricle is maximally filled – is normal, defined as greater than 50%; [1] this may be ... Diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF), is a condition in which your heart’s main pumping chamber (left ventricle) becomes stiff and unable to fill properly.
Hypertension in particular is a strong risk factor; 80 to 90 percent of patients with HFpEF are hypertensive. Historically, HFpEF was termed diastolic heart failure; however, recent investigations suggest a more complex and heterogeneous pathophysiology. Roughly half of people with heart failure have preserved ejection fraction (HFpEF). Get answers to common questions about treatments, outlook, and more.
hfpef medical abbreviation, Heart Failure with Preserved Ejection Fraction (HFpEF): patients with an LVEF ≥50% with evidence of spontaneous or provokable increased left ventricular filling pressures (LVFPs), characterized by elevated natriuretic peptides or hemodynamic measurements. [1]
